Come up with a name for your new list and we'll add to it:
Shape Pharmaceuticals was acquired by
TetraLogic Pharmaceuticals on April 07, 2014.
Shape Pharmaceuticals is developing SHP-141, a novel, topical HDAC inhibitor, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL). The developm…